AML1-ETO downregulates the granulocytic differentiation factor C/EBP alphain t(8;21) myeloid leukemia

Citation
T. Pabst et al., AML1-ETO downregulates the granulocytic differentiation factor C/EBP alphain t(8;21) myeloid leukemia, NAT MED, 7(4), 2001, pp. 444-451
Citations number
45
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research General Topics
Journal title
NATURE MEDICINE
ISSN journal
10788956 → ACNP
Volume
7
Issue
4
Year of publication
2001
Pages
444 - 451
Database
ISI
SICI code
1078-8956(200104)7:4<444:ADTGDF>2.0.ZU;2-A
Abstract
The transcription factor CCAAT/enhancer binding protein alpha, or C/EBP alp ha, encoded by the CEBPA gene, is crucial for the differentiation of granul ocytes. Conditional expression of C/EBP alpha triggers neutrophilic differe ntiation, and Cebpa knockout mice exhibit an early block in maturation. Dom inant-negative mutations of CEBPA have been found in some patients with acu te myeloid leukemia (AML), but not in AML with the t(8;21) translocation wh ich gives rise to the fusion gene RUNX1-CBF2T1 (also known as AML1-ETO) enc oding the AML1-ETO fusion protein. RUNX1-CBF2T1 positive-AML blasts had eig ht-fold fewer CEBPA RNA levels and undetectable C/EBP alpha protein levels compared with other subgroups of AML patients. Conditional expression of RU NX7-CBF2T7 in U937 cells downregulated CEBPA mRNA, protein and DNA binding activity. AML1-ETO appears to suppress C/EBP alpha expression indirectly by inhibiting positive autoregulation of the CEBPA promoter. Conditional expr ession of C/EBP alpha in AML1-ETO-positive Kasumi-1 cells results in neutro philic differentiation. We suggest that restoring C/EBP alpha expression wi ll have therapeutic implications in RUNX1-CBF2T1-positive leukemias.